<DOC>
	<DOCNO>NCT00429481</DOCNO>
	<brief_summary>To assess efficacy , immune response safety 2 dos HRV vaccine ( different concentration ) healthy infant age approximately 3 month previously uninfected human rotavirus .</brief_summary>
	<brief_title>Assess Efficacy , Immune Response &amp; Safety 2 Doses Oral Live Attenuated HRV Vaccine Different Viral Concentrations Healthy Infants</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy infant 11 17 week age time first vaccination , bear normal gestation period ( 36 42 week ) . Written inform consent obtain parent guardian subject . Use investigational nonregistered drug vaccine study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Previous vaccination history intercurrent diphtheria , tetanus , pertussis , polio and/or Hib . Chronic administration immunosuppressant immunemodifying drug since birth . ( Topical steroid allow . ) Use antibiotics period start 7 day dose vaccine ( ) end 7 day . Any clinically significant history chronic gastrointestinal disease include uncorrected congenital malformation GI tract serious medical condition determine investigator . Any confirm suspected immunosuppressive immunodeficient condition , include HIV infection . History allergic disease reaction likely exacerbated component vaccine . GE within 7 day precede study vaccine administration ( warrant deferral vaccination ) . Household contact immunosuppressed individual pregnant woman . Administration immunoglobulins and/or blood product since birth plan administration study period . Previous confirm occurrence RV GE .</criteria>
	<gender>All</gender>
	<minimum_age>11 Weeks</minimum_age>
	<maximum_age>17 Weeks</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Oral live attenuate human rotavirus vaccine</keyword>
	<keyword>Gastroenteritis</keyword>
	<keyword>Vomiting</keyword>
</DOC>